Longevity
Eli Lilly's $2.75 Billion AI Bet on Anti-Aging Drugs Signals a Major Shift in Pharmaceutical Priorities
Eli Lilly's $2.75B AI deal with Insilico Medicine targets age-related diseases. How AI is transforming longevity drug discovery and what it means for patients.
This story was reported by Medical Daily. EUROPES curates Europe's most relevant coverage — read the full report at the original source.
Read full coverage at Medical Daily →